1. 3- (1- {3- [5- (1-Methyl-piperidin-4-ylmethoxy) -pyrimidin-2-yl] benzyl} -6-oxo-1,6-dihydro-pyridazin-3-yl ) -benzonitrile or a pharmaceutically acceptable salt and / or solvate thereof for use in the treatment of hepatocellular carcinoma (HCC) .2. 3- (1- {3- [5- (1-methyl-piperidin-4-ylmethoxy) pyrimidin-2-yl] benzyl} -6-oxo-1,6-dihydro-pyridazin-3-yl hydrochloride hydrate ) -benzonitrile for use in the treatment of hepatocellular carcinoma (HCC) .3. 3- (1- {3- [5- (1-Methyl-piperidin-4-ylmethoxy) -pyrimidin-2-yl] benzyl} -6-oxo-1,6-dihydro-pyridazin-3-yl) - benzonitrile according to claim 1 or 2, wherein the compound is administered to the patient in an amount of from 100 mg to 800 mg per day. 3- (1- {3- [5- (1-Methyl-piperidin-4-ylmethoxy) -pyrimidin-2-yl] benzyl} -6-oxo-1,6-dihydro-pyridazin-3-yl) - benzonitrile according to claim 1 or 2, wherein the compound is administered orally. Use of 3- (1- {3- [5- (1-methyl-piperidin-4-ylmethoxy) -pyrimidin-2-yl] benzyl} -6-oxo-1,6-dihydro-pyridazin-3-yl) -benzonitrile or a pharmaceutically acceptable salt and / or solvate thereof for the manufacture of a medicament for the treatment of hepatocellular carcinoma (HCC) .6. Use of 3- (1- {3- [5- (1-methyl-piperidin-4-ylmethoxy) pyrimidin-2-yl] benzyl} -6-oxo-1,6-dihydro-pyridazin-3- hydrochloride hydrate il) -benzonitrile for the manufacture of a medicament for the treatment of hepatocellular carcinoma (HCC) .7. The use according to claim 5 or 6, wherein the compound is administered to the patient in an amount of from 100 mg to 800 mg per day. The use of claim 5 or 6, wherein the compound is administered orally.1. 3-(1-{3-[5-(1-Метил-пиперидин-4-илметокси)-пиримидин-2-ил]-бензил}-6-оксо-1,6-дигидро-пиридазин-3-ил)-бензонитрил или его фармацевтически приемлемая соль и/или сольват для применения в лечении гепатоцеллюлярной карциномы (ГЦК).2. Гидрат гидрохлорида 3-(1-{3-[5-(1-метил-пиперидин-4-илметокси)-пиримидин-2-ил]-бензил}-6-оксо-1,6-дигидро-пиридазин-3-ил)-бензонитрила
